Erwan Bezard Selected Research

Levodopa (L Dopa)

4/2022	Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia.
1/2021	Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson's Disease.
1/2021	Involvement of Autophagy in Levodopa-Induced Dyskinesia.
1/2021	Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.
1/2021	L-DOPA regulates α-synuclein accumulation in experimental parkinsonism.
1/2021	Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson's disease and L-Dopa induced dyskinesia.
1/2020	RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.
1/2020	Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
1/2020	µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.
1/2020	Models of hyperkinetic disorders in primates.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erwan Bezard Research Topics

Disease

138	Parkinson Disease (Parkinson's Disease) 04/2022 - 03/2003
78	Dyskinesias (Dyskinesia) 04/2022 - 11/2003
24	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 09/2005
24	Parkinsonian Disorders (Parkinsonism) 01/2022 - 06/2004
17	Synucleinopathies 11/2022 - 07/2014
9	Multiple System Atrophy 11/2022 - 05/2017
6	Dementia (Dementias) 01/2022 - 07/2014
5	Dystonia (Limb Dystonia) 02/2020 - 02/2004
4	Disease Progression 11/2021 - 11/2010
4	Huntington Disease (Huntington's Disease) 01/2020 - 06/2004
4	Alzheimer Disease (Alzheimer's Disease) 08/2017 - 04/2013
3	Insulin Resistance 01/2022 - 05/2017
3	Brain Diseases (Brain Disorder) 01/2021 - 01/2017
3	Epilepsy (Aura) 01/2021 - 11/2003
3	Nervous System Diseases (Neurological Disorders) 01/2020 - 09/2004
3	Mental Disorders (Mental Disorder) 01/2019 - 12/2009
3	Gaucher Disease (Gaucher's Disease) 01/2017 - 06/2013
3	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 01/2017 - 12/2009
2	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 01/2021
2	Neuroinflammatory Diseases 01/2022 - 01/2017
2	Sleep Wake Disorders 01/2022 - 10/2009
2	Chronic Pain 01/2021 - 03/2003
2	Pain (Aches) 01/2019 - 08/2011
2	Tremor (Tremors) 10/2018 - 12/2009
2	Hypokinesia (Bradykinesia) 10/2018 - 11/2016
2	Proteostasis Deficiencies 01/2018 - 10/2017
2	Gambling (Pathological Gambling) 01/2017 - 12/2009
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2017 - 08/2014
2	Neoplasms (Cancer) 09/2016 - 09/2005
2	Inflammation (Inflammations) 08/2014 - 12/2009
2	Disorders of Excessive Somnolence (Hypersomnia) 03/2014 - 10/2009
2	Cognitive Dysfunction 04/2013 - 02/2005
2	Chorea (Rheumatic Chorea) 07/2009 - 02/2004
1	Frontotemporal Dementia (Semantic Dementia) 11/2022

Drug/Important Bio-Agent (IBA)

86	Levodopa (L Dopa)FDA LinkGeneric 04/2022 - 03/2003
42	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 04/2003
36	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2020 - 11/2003
27	SynucleinsIBA 11/2022 - 06/2013
27	Proteins (Proteins, Gene)FDA Link 01/2022 - 10/2006
11	Dopamine Receptors (Dopamine Receptor)IBA 06/2015 - 11/2004
9	alpha-SynucleinIBA 01/2022 - 07/2009
9	Therapeutic UsesIBA 01/2020 - 11/2003
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2010
7	Serotonin (5 Hydroxytryptamine)IBA 04/2016 - 12/2008
6	Oxidopamine (6 Hydroxydopamine)IBA 01/2020 - 03/2004
5	Amyloid (Amyloid Fibrils)IBA 11/2022 - 08/2017
5	NeuropeptidesIBA 04/2022 - 11/2012
5	Pharmaceutical PreparationsIBA 05/2017 - 09/2010
5	Messenger RNA (mRNA)IBA 01/2017 - 03/2004
4	Neurotransmitter Agents (Neurotransmitter)IBA 11/2019 - 12/2009
4	Glucosylceramidase (Glucocerebrosidase)IBA 01/2017 - 01/2016
4	Electron Transport Complex IV (Cytochrome c Oxidase)IBA 12/2010 - 03/2004
4	Levetiracetam (Keppra)FDA LinkGeneric 07/2004 - 11/2003
3	Peptides (Polypeptides)IBA 04/2022 - 02/2014
3	Insulin (Novolin)FDA Link 01/2022 - 07/2014
3	Serine (L-Serine)FDA Link 01/2022 - 05/2017
3	NociceptinIBA 01/2020 - 11/2012
3	Opioid Analgesics (Opioids)IBA 01/2020 - 04/2007
3	EnzymesIBA 10/2018 - 11/2016
3	eltoprazineIBA 10/2017 - 07/2013
3	Dopamine Agonists (Dopamine Agonist)IBA 01/2017 - 02/2008
3	Neuroprotective AgentsIBA 11/2010 - 09/2004
2	TachykininsIBA 04/2022 - 01/2020
2	Dynorphins (Dynorphin)IBA 04/2022 - 01/2020
2	Phosphotransferases (Kinase)IBA 01/2022 - 08/2014
2	Insulin Receptor Substrate ProteinsIBA 01/2022 - 05/2017
2	Cholinergic Agents (Cholinergics)IBA 01/2021 - 07/2009
2	Opioid Receptors (Opioid Receptor)IBA 01/2020 - 04/2007
2	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2019 - 01/2019
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 09/2009
2	Dopamine Agents (Dopaminergic Agents)IBA 01/2019 - 10/2006
2	2- (2- furanyl)- 7- (2- (4- (4- (2- methoxyethoxy)phenyl)- 1- piperazinyl)ethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo(1,5- c)pyrimidine- 5- amineIBA 10/2017 - 04/2016
2	Protein AggregatesIBA 07/2017 - 03/2014
2	Insulin-Like Growth Factor I (IGF-1)IBA 05/2017 - 07/2014
2	Glucagon-Like Peptide 1 (GLP 1)IBA 05/2017 - 07/2014
2	Nucleic AcidsIBA 01/2017 - 08/2014
2	Lovastatin (Mevacor)FDA LinkGeneric 06/2016 - 04/2008
2	Simvastatin (Zocor)FDA LinkGeneric 06/2016 - 04/2013
2	NeurotoxinsIBA 02/2016 - 12/2003
2	Muscarinic M4 ReceptorIBA 01/2016 - 11/2015
2	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)IBA 01/2016 - 07/2014
2	6- fluoro- 2- (4- (pyridin- 2- yl)but- 3- yn- 1- yl)imidazo(1,2- a)pyridineIBA 01/2016 - 07/2014
2	Proteasome Endopeptidase Complex (Proteasome)IBA 06/2015 - 01/2012
2	GTP-Binding Proteins (G-Protein)IBA 05/2015 - 10/2014
2	Amantadine (Aman)FDA LinkGeneric 05/2014 - 07/2004
2	fenobamIBA 05/2014 - 09/2010
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 04/2013 - 08/2010
2	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 11/2012 - 08/2010
2	Glutamate Receptors (Glutamate Receptor)IBA 11/2012 - 02/2010
2	rotigotine FDA Link 02/2008 - 02/2007
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 02/2008 - 05/2003
2	ropinirole (Requip)FDA LinkGeneric 12/2007 - 11/2003
2	PolyphenolsIBA 12/2007 - 09/2005
2	TeaIBA 12/2007 - 09/2005
2	Deoxyglucose (2 Deoxy D glucose)IBA 03/2007 - 02/2005
2	Minocycline (Cyclops)FDA LinkGeneric 09/2004 - 06/2004
2	Dihydroxyphenylalanine (Dopa)IBA 07/2004 - 02/2004

Therapy/Procedure

33	Therapeutics 11/2021 - 11/2003
4	Denervation 01/2020 - 03/2003
2	Drug Therapy (Chemotherapy) 04/2013 - 11/2010